Triastek Achieves Positive Outcome in Trial of its 3D Printed Medication on Human Subjects

Share this story

Triastek, a Chinese pharmaceutical developer, has completed the first in human study for its additive-manufactured ulcerative colitis (UC) treatment T21. The company printed the drug using its proprietary Melt Extrusion Deposition (MED) platform.

T21 has successfully undergone an FIH (first in human) trial, which is the practice of administering an experimental drug to a small group of people for the first time. This is an important step for the advancement of a drug to market readiness.

The MED platform enables Triastek to produce pharmaceutical-grade medications at a much lower cost than traditional large-scale production. Instead of investing in costly manufacturing equipment and consumables, products can be printed in small batches using the same technology seen in 3D printing.

The results of the T21 FIH trial will pave the way for additional studies and the production of other therapeutic possibilities using MED. Moving forward, Triastek is dedicated to providing the world with a more cost-effective, accessible, and personalized route to medical treatments. Pushing the boundaries of the possibilities with 3D printing lies at the heart of Triastek’s mission – to provide better, more localized drug delivery for specialized conditions, including ulcerative colitis.

One of the company’s most notable products is T21, a novel medication specifically designed for localized release within the colon. Leveraging the potential of additive manufacturing, these pills are specially designed to the exact geometry necessary for targeting the exact area of the body it needs to.

Additionally, the manufacturing process allows a level of control over the rate of release of the active ingredients that is impossible to achieve with traditional oral medications currently available in the market. In patients with ulcerative colitis, this is invaluable, as it can significantly improve their lives in a way that no existing drug can.

Therefore, it can be said that at this point, Triastek has put a tremendous amount of focus on developing drugs that could only be crafted with 3D printing, to facilitate their more precise and timely delivery. This is especially true for T21, which is targeted toward individuals suffering from UC, and is tailored to fit the unique needs of those patients. Triastek has made a tremendous breakthrough in the treatment of Ulcerative Colitis with their recent findings from the FIH study. With the evidence gathered showing that upon consumption, their T21 tablets are delivered and released directly to the colon, this could have wide-ranging implications.

Not only does this mean that UC patients can now find a reliable and effective treatment for their condition, it could also be utilized to boost Triastek’s efforts for a New Drug Application (NDA). The company’s goal to gain approval for the commercial launch of T21 just got a huge boost.

As one of the foremost problems associated with oral drug delivery is slow and inconsistent absorption in the body, Triastek’s findings are a major step forward. Clinical trials have now demonstrated that their patented, pH-sensitive drug release system eliminates this issue, efficiently and safely delivering high concentrations of T21 into the colon.

The results of the FIH study not only show the reliable and safe delivery of the drug, but also the consistent and prompt relief provided to patients. This is set to have a huge impact on the lives of those dealing with Ulcerative Colitis, finally providing them with a reliable treatment. In addition to this, approval for a New Drug Application also looks like a more achievable goal than ever for Triastek. Triastek, a healthcare technology innovator, recently completed a First-in-Human (FIH) study for their colon-targeted drug delivery technology, utilizing their proprietary Manufacturing Extractable Deposable (MED) process. Triastek’s co-founder and chief scientific officer, Professor Xiaoling Li, is excited by the recent findings.

“The data with T21 verifies the precise colon delivery capability of the MED process,” said Professor Li. “Our 3D printing processes can bring technical solutions to pharmaceutical companies for efficient product development of optimized drug delivery, ultimately leading to the ability to provide patients with more clinically valuable medicines. We believe the MED process can soon become the novel drug delivery system of choice for such new products.”

Triastek’s advanced 3D printing technology enables the creation of complex products with micro-scale details. This technology, when combined with the MED process, provides an innovative and fast way for drug manufacturers to develop colon-targeted medicines. Such medicines, made accessible using the MED process, can provide more clinically valuable solutions to patients suffering from a range of illnesses.

Triastek strives to use technology to bring innovative solutions to the pharmaceutical sector and, with the FIH study now complete, the potential of the MED process is solidified. Moving forward, the company hopes to continue showcasing how advanced 3D printing processes are capable of enriching healthcare solutions with better delivery. In simple terms, a new technology called T21 from Triastek reduces the chances of undesirable side effects from using medications. What this means for drug companies is that they now have access to a drug production process that is easier and safer than ever before.

These advantages of the T21 platform from Triastek are in its ability to reduce systemic exposure that can be caused when medication is released into the rest of the body. By controlling systemic exposure, T21 ensures that drugs can be administered with precision and accuracy for more effective and safer treatments.

Dr. Senping Cheng, CEO of Triastek, believes that using T21 could substantially improve quality control within the pharmaceutical industry, leading to many potential supply chain advantages. For example, with greater precision in drug administration, pharmaceutical companies can reduce the amount of wasted product because of improper quality control. In turn, this would reduce drug costs and increase the availability of needed medications.

In conclusion, Triastek’snew technology called T21 could potentially revolutionize the use of medications by pharmaceutical companies. By mitigating systemic exposure, T21 offers precision and accuracy for drug administration, leading to greater quality control and fewer wasted products. This technology could have far-reaching benefits in the drug production industry and is worth advanced exploration. Creating a paradigm shift in the pharmaceuticals industry is no mean feat. With decades-old regulations in place, introducing emerging technologies such as additive manufacturing (AM) for the manufacturing of medications presents a huge challenge. It’s a task that is more easily said than done.

That said, the need has never been greater. With supply issues increasingly rampant in the industry, pharma companies and governments must work together to embrace advanced automation technologies. This includes not only using AM for the production of medications, but also for the implementation of new processes that promote product quality and public safety.

Of course, any changes must be undertaken with the utmost care and respect for existing pharma regulations. Nonetheless, for companies who have already seen positive results from the use of advanced manufacturing technologies, the adoption of these innovations should be considered a priority.

Ultimately, medications must always be designed and produced responsibly and with patient safety in mind. By utilizing smart automation technologies, such as AM, pharma firms can reach a new level of efficiency and product quality while still adhering to principles of safety first. Breaking news: In 2022, drug research and biotechnology company Triastek partnered with Eli Lilly, a global pharma giant, to explore new uses for the MED platform. It has only been a year since this announcement, but something has changed: The FDA has rejected Eli Lilly’s application to approve its new UC drug, mirikuzmab. The exact reason given by the FDA is that Eli Lilly’s manufacturing operations in Branchburg, NJ have glossed over proper quality control. This could signal a potential challenge to the company’s ability to remain competitive in the booming pharmaceutical industry.

Eli Lilly is one of the world’s largest drug developers and manufacturers of pharmaceuticals. Their partnership with Triastek released a number of cost-effective and innovative medicines on the market, making it a competitive player in the industry. As a result, mirikuzmab offered hope to those with UC as the drug may provide much needed relief.

It’s a disappointing setback for Eli Lilly, but Triastek remains dedicated to the research and development behind the platform. The team has made tremendous progress in establishing new applications for the MED platform over the past year. This partnership isn’t simply about developing more innovative drugs, however– it is now a necessity for Eli Lilly to ensure that its quality control measures meet mandated safety standards set by the FDA and other agencies in order to remain competitive in the pharmaceutical industry.

This latest rejection is a major blow for Eli Lilly, but it also serves as a reminder that proper quality control measures must be taken seriously by all drug developers and manufacturers. We’ll see if Eli Lilly is able to overcome this setback and move forward in the industry, but in the meantime, it’s important to recognize the importance of quality assurance with any drug or product. Close-up of a black bird against blue sky

Group of black birds flying

Behind the beauty of nature, there are a variety of animals that live and thrive. Birds in particular are incredibly diverse and can live in a variety of places and climates. Triastek has wonderfully captured two easy-on-the-eye photos of birds.

The close-up on a single black bird on a blue sky makes the viewer aware of the unique beauty on individual birds. This photo captures the detail on the feathers, each looking individual to one another. Moreover, the photo gently and gracefully captures the birds serene pose, outstretched wings and overall beauty.

The second photo is a group of black birds gliding gracefully in the sky. Watching birds in flight is always a breathtaking experience and Triastek has wonderfully captured the gliding beauty of all these birds, providing a viscerally powerful view for the viewer.

Whether you love birds or nature photography in general, Triastek has wonderfully provided us with such beautiful photos that can remind viewers of the beauty of nature. Are you looking to stay informed about the latest 3D printing industry news and offers? You’ve come to the right place!

We provide current information about 3D printing technology and products, including the newest products and services from third party vendors. This way, you can stay up-to-date with the latest industry trends and find offers to meet your 3D printing needs.

Whether you’re a professional seeking new ways to innovate or a hobbyist looking to level up your 3D printing skills, you can find reliable information that fits your needs. Our website includes articles on the latest 3D printing technology, product reviews, and helpful hints for beginners.

We also provide vendors who offer discounts and promotions on 3D printing materials and accessories. With our help, you can make informed decisions and find the right products and services to improve your 3D printing experience.

Our goal is to help make 3D printing technology more accessible and affordable for everyone. Stay informed: visit our website to learn more about 3D printing news and offers!


Share this story

Leave a Reply

Your email address will not be published. Required fields are marked *